囊腫纖維化藥物市場規模、佔有率和成長分析（按藥物類別、給藥途徑、分銷管道和地區）- 產業預測 2025-2032

2023 年囊腫纖維化藥物市場規模價值 65 億美元，預計將從 2024 年的 74.2 億美元成長到 2032 年的 213.1 億美元，預測期內（2025-2032 年）的複合年成長率為 14.1%。

隨著囊性纖維化 (CF) 盛行率的上升和治療率的提高，囊腫纖維化(CF) 藥物市場預計將經歷顯著成長。公共和私營部門對研發的資金籌措增加以及強力的非營利措施進一步支持了市場擴張。隨著患者數量逐年增加，對有效治療方法的需求也隨之增加，現有藥物類別（如 CFTR 調節劑、黏液溶解劑和抗生素）的利用率也隨之增加。此外，各大製藥公司不斷增加的創新治療藥物和旨在擴大客戶群的持續研究也促進了市場的發展。一些慈善組織積極支持 CF 研究和發展也是推動市場成長的關鍵因素。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析
• 技術分析

囊腫纖維化藥物市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概況
• 抗感染藥物
• CFTR調變器
• 胰酵素補充劑
• 黏液溶解劑
• 支氣管擴張劑

囊腫纖維化藥物市場規模（依給藥途徑及複合年成長率） (2025-2032)

• 市場概況
• 口服
• 吸入

囊腫纖維化藥物市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

囊腫纖維化藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Vertex Pharmaceuticals（USA）
• AbbVie（USA）
• Gilead Sciences（USA）
• Roche（Switzerland）
• Teva Pharmaceutical Industries（Israel）
• Mylan（now Viatris）（USA）
• Novartis AG（Switzerland）
• AstraZeneca（UK）
• Alaxia.
• Allergan（now part of AbbVie）（Ireland）
• Beyond Air Inc.（USA）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co. Inc.（USA）
• Alcresta Therapeutics Inc.（USA）
• Chiesi（Italy）
• Nestle HealthScience（Switzerland）
• Pharmaxis Ltd.（Australia）
• PTC Therapeutics, Inc.（USA）
• Insmed, Inc.（USA）
• Grifols SA（Spain）

結論和建議

Cystic Fibrosis Therapeutics Market size was valued at USD 6.5 billion in 2023 and is poised to grow from USD 7.42 billion in 2024 to USD 21.31 billion by 2032, growing at a CAGR of 14.1% during the forecast period (2025-2032).

The cystic fibrosis (CF) therapeutics market is poised for significant growth driven by the rising prevalence of CF and an increase in treatment rates. Enhanced funding for research and development from both public and private sectors, along with robust nonprofit initiatives, is further propelling market expansion. The demand for effective therapies is increasing due to a year-on-year rise in patient numbers, leading to greater utilization of existing drug classes, including CFTR modulators, mucolytics, and antibiotics. Additionally, a growing pipeline of innovative therapy compositions from leading pharmaceutical companies and ongoing studies aimed at broadening their customer base will contribute to market dynamics. The active role of several charitable organizations in supporting CF research and development is also a crucial factor in fostering market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cystic Fibrosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cystic Fibrosis Therapeutics Market Segments Analysis

Global Cystic Fibrosis Therapeutics Market is segmented by Drug Class, Route Of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-infectives, CFTR Modulators, PancreaticenzymeSupplements, Mucolytics and Bronchodilators. Based on Route Of Administration, the market is segmented into Oral and Inhaled. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cystic Fibrosis Therapeutics Market

The cystic fibrosis therapeutics market is predominantly driven by the rising incidence of cystic fibrosis, a genetic disorder that significantly impacts the respiratory, digestive, and reproductive systems. As this debilitating condition remains incurable, patients necessitate continuous treatment throughout their lives, which in turn fuels the demand for effective cystic fibrosis therapeutics. As more individuals are diagnosed and require ongoing care, the market is expected to see substantial growth, underscoring the critical need for innovative treatments and supportive therapies to enhance the quality of life for those affected by this chronic illness.

Restraints in the Cystic Fibrosis Therapeutics Market

The elevated prices associated with cystic fibrosis treatments, especially innovative targeted therapies, pose a significant challenge to patient access. This situation raises crucial concerns regarding the affordability of these essential medications and their influence on healthcare systems. Many patients are unable to obtain necessary treatments due to the financial burden, which can lead to potential disparities in healthcare outcomes. As a result, these high costs not only affect individual patients but also strain the resources of healthcare providers and insurers, ultimately complicating the management of cystic fibrosis and limiting the overall efficacy of available therapies.

Market Trends of the Cystic Fibrosis Therapeutics Market

The cystic fibrosis therapeutics market is witnessing a significant shift towards personalized medicine, driven by advancements in genomic research and a deeper understanding of the disease's genetic underpinnings. As more targeted therapies emerge that cater to specific mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, patients are increasingly seeking tailored treatment options that provide enhanced efficacy and improved outcomes. This trend is anticipated to escalate, encouraging pharmaceutical companies to invest in innovative research and development, ultimately transforming cystic fibrosis management. Consequently, a robust growth trajectory is expected in the personalized medicines segment, solidifying its prominence in the evolving therapeutics landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Technology Analysis

Global Cystic Fibrosis Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Anti-infectives
• CFTR Modulators
• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators

Global Cystic Fibrosis Therapeutics Market Size by Route Of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Inhaled

Global Cystic Fibrosis Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cystic Fibrosis Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Route Of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Route Of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route Of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route Of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route Of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (now Viatris) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alaxia.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (now part of AbbVie) (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beyond Air Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcresta Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chiesi (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle HealthScience (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaxis Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insmed, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations